Kingsport, TN (January 30, 2013) – Intellectual Property Executives (IPE) announced on Wednesday that it has been given approval by the U.S. Food and Drug Administration to begin Phase-2 clinical trials for BCT303, its lead T3 candidate to treat hypothyroidism. “What makes BCT303 unique is that it’s the first once-a-day T3 drug with improved stability,” says Eric Latham, Founder and CEO of IPE. “It’s also quicker to market, as a 505(b)(2) drug.” Phase-2 clinical trials for BCT303 will take place at Georgetown University Hospital. They will begin in February and are expected to span only six weeks. IPE has also begun preparing an investigational new drug (IND) application for BCT304, its lead T4 candidate to treat hypothyroidism. Both BCT303 and BCT304 are new, branded drugs that use IPE’s pending patent for sustained-release and improved product stability. This platform technology will be used for additional 505(b)(2) applications, including pain-relief, anti-inflammation and others. IPE’s Research & Development division is based on six pending patents for platform technology that are fully-owned by IPE. These patents have led to the discovery and development of drug candidates addressing the following therapeutic arenas: Breast Cancer, Parkinson’s disease, Alzheimer’s disease, Hypothyroidism, Depression, ADHD, Ischemic Bowel Disease, Inflammatory Disease, PTSD, Wound-Healing and Tissue Repair, and Hypo-Metabolism. IPE is a family-owned and operated, pharmaceutical drug discovery and development company located in Kingsport, Tennessee (USA). To learn more, visit www.ipeamerica.com.